Bio-Techne (TECH) Q4 2025 10-Q Quarterly Report

Filed: Feb 4, 2026Period ending Dec 31, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Bio-Techne (TECH) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 4, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Bio-Techne Q4 2025 10-Q Analysis

Management Discussion & Analysis

• Revenue $295.9M flat YoY for Q2 FY25; six months $582.4M, down 1% YoY; organic revenue flat in quarter, slight FX and held-for-sale impacts
• Operating margin Protein Sciences 39.3% vs 41.2% YoY Q2; Diagnostics 10.4% vs 3.9% YoY Q2, drove margin improvement overall

+3 more insights

Risk Factors

• Continued supply chain disruptions risk impacting production schedules carried from 10-K
• Dependence on third-party suppliers with potential for raw material shortages carried from 10-K

+2 more insights

Bio-Techne Q4 2025 Quarterly Financials
XBRL

Revenue

$296M

▼ -0.4% YoY▲ +3.3% QoQ

Net Income

$38M

▲ +8.9% YoY▼ -0.5% QoQ

Gross Margin

64.6%

▼ -63bp YoY▼ -100bp QoQ

Operating Margin

18.4%

▲ +244bp YoY▲ +178bp QoQ

Net Margin

12.8%

▲ +110bp YoY▼ -48bp QoQ

ROE

1.9%

▲ +21bp YoY

Total Assets

$2.5B

▼ -5.5% YoY

EPS (Diluted)

$0.25

▲ +19.0% YoY▲ +4.2% QoQ

Operating Cash Flow

$82M

▼ -2.3% YoY▲ +198.8% QoQ

Source: XBRL data from Bio-Techne Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Bio-Techne

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.